A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
Status:
Completed
Trial end date:
2019-11-20
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared
to placebo, in lowering fasting triglyceride (TG) levels in patients with fasting TG levels
≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment.
Approximately 615 subjects will be screened to obtain 245 randomized subjects following a
2.5:1 treatment allocation ratio (CaPre: placebo).